Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab in Steroid-Resistant or Relapsing Thyroid Associated Ophthalmopathy
NCT02378298Phase 4Completed
- Sponsor
- University of Gothenburg
- Start
- Dec 2011
- Primary completion
- Sep 2019
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of rituximab in thyroid associated ophthalmopathy (TAO), sponsored by University of Gothenburg. Started Dec 2011; status: completed.
02
Drugs
rituximab
03
Conditions
thyroid associated ophthalmopathy (TAO)
Beyond the preview
Go deeper on NCT02378298.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02378298.